Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

REVEALED: Akebia rapeutics | Rare Historical Photos

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers

Benzinga · Jun 30, 2022

Looking Into Akebia Therapeutics's Return On Capital Employed

According to Benzinga Pro data, during Q1, Akebia Therapeutics (NASDAQ:AKBA) posted sales of $61.70 million. Earnings were up 11.68%, but Akebia Therapeutics still reported an overall loss of $62.42 million.

Benzinga · Jun 2, 2022

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers

Benzinga · May 31, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Expert Ratings for Akebia Therapeutics

Over the past 3 months, 4 analysts have published their opinion on Akebia Therapeutics (NASDAQ:AKBA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · May 16, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022

Upgrades

Benzinga · Mar 31, 2022

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga · Mar 30, 2022

Akebia Therapeutics Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Akebia Therapeutics (NASDAQ:AKBA) reported Q4 sales of $59.60 million. Earnings fell to a loss of $70.68 million, resulting in a 18.7% decrease from last quarter.

Benzinga · Mar 3, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

Benzinga

Organisations

Advanced Micro Devices

From analysis to the latest developments in health,
read the most diverse news in one place.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.